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BRUCE BLAZAR TO PRESENT
DONNALL THOMAS LECTURE
A leader in the identification of im-
mune mechanisms for GvHD genera-
tion and bone marrow graft rejection
will present the annual E. Donnall
Thomas Lecture at the 2005 Tandem
BMT Meetings. Bruce Blazar, MD, will
speak on “Tracking and Manipulating
T-Cell Alloresponses” on Saturday,
Feb. 12.
A professor in the department of
pediatrics and associate director of
the Division of Blood and Marrow
Transplantation at the University of
Minnesota, Dr. Blazar has developed
biological and pharmacological strat-
egies to block alloresponses and facil-
itate immune recovery posttransplan-
tation that are being translated into
clinical care.
Registration and housing informa-
tion for the Feb. 10-14 Tandem BMT
Meetings in Keystone, Colo., are on-
line at www.asbmt.org.
SPECIAL SESSION FOR TRAINEES AT
TANDEM BMT MEETINGS
A workshop for physicians-in-train-
ing and post-doctoral fellows in blood
and marrow transplantation will be
held on the opening day of the 2005
Tandem BMT Meetings in Keystone,
Colo.
The first part of the workshop will
be a “user’s guide” for trainees attend-
ing the meetings for the first time.
Recommendations will be offered on
which sessions to attend, how to par-
ticipate, and what to take away from
the sessions. The workshop also will
include small-group discussions with
senior transplanters on career oppor-
tunities and alternatives.
The session will be chaired by John
DiPersio, MD, of Washington Univer-
sity of St. Louis and is scheduled for
2:00 PM to 3:30 PM on Thursday, Feb.
10.
NEW INVESTIGATOR EVALUATES
NATURAL KILLER CELL ACTIVITY
The recipient of an ASBMT/Roche
New Investigator Award has submit-
ted a final report on his research on
differentiation and destruction of can-
cer cells.
Subramaniam Malarkannan, PhD,
an assistant professor of medicine at
the Medical College of Wisconsin,
and his team have been exploring the
role of natural killer cells as the first
line of defense in the immune re-
sponse.
His research has explored the inter-
action between the H60 activating
ligand and the NKG2D receptor,
which seems to play an important
role in the process by which NK cells
recognize other cells as “self” or “non-
self.” A forthcoming study in Blood
reports that cytotoxic effects involving
NKG2D are influenced by the level of
H60 as well as by the MHC class I
molecules expressed on target cells.
Levels of H60 on target cells deter-
mine the ability of Ly49 receptors to
inhibit the actions of NKG2D. The ef-
fects of NKG2D on the cell-killing ef-
fects of NK cells appear to result from
“a fine balance between activating
and inhibitory receptors,” Dr. Malar-
kannan and his co-authors con-
cluded.
In a paper published last year in
Immunogenetics, Dr. Malarkannan
and his group described a single nu-
cleotide polymorphism resulting in
greatly reduced expression of the one
allelic H4 minor histocompatibility an-
tigenic peptide. This discovery may
aid in developing new approaches to
overcoming strong T-cell–mediated
reactions elicited by minor histocom-
patibility antigen disparities in trans-
plantation. Other forthcoming publi-
cations provide updates on minor
histocompatibility antigens as barriers
to transplantation, as well as potential
targets for immunomodulation ap-
proaches.
FDA ISSUES RULES FOR ‘GOOD
TISSUE PRACTICE’
The U.S. Food and Drug Adminis-
tration has published the new final
rule on “Good Tissue Practice,” the
last of three sets of regulations to be
finalized as part of the agency’s plan
for safe management of human cells
and tissues. The rule addresses meth-
ods, facilities, and controls used to
manufacture human tissue and cellu-
lar products. They will be fully imple-
mented on May 25, 2005.
The new rule requires manufactur-
ers to recover, process, store, label,
package, and distribute human cells,
tissues, and cellular and tissue-based
products (HCT/Ps) in a way that pre-
vents the introduction, transmission,
and spread of communicable dis-
eases. The regulations apply to a
broad range of these products, in-
cluding musculoskeletal tissue, cor-
neas, human heart valves, dura mater
(lining of the brain), and cellular ther-
apies.
The final rule follows the earlier
publication of FDA’s final regulations
on registration of human tissue facili-
ties and the eligibility of human tissue
donors. The rule also includes a re-
quirement for manufacturers to re-
port certain adverse reactions and
HCT/P deviations, to have labeling
that contains accurate and complete
information, and to allow FDA inspec-
tions to ensure compliance with reg-
ulations.
FDA’s first regulations specifically
addressing human tissues were pro-
mulgated in December 1993. These
regulations required that tissue do-
nors be tested for certain communi-
cable diseases such as HIV and hepa-
titis, and screened for behavioral risk
factors.
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